Chardan Capital analyst Keay Nakae maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report) today and set a price target of $3.00. The company’s shares closed yesterday at $0.78.
According to TipRanks, Nakae is an analyst with an average return of -0.6% and a 36.96% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Seres Therapeutics, Avidity Biosciences, and Pear Therapeutics.
Currently, the analyst consensus on SAB Biotherapeutics is a Moderate Buy with an average price target of $3.50, representing a 348.72% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.
See the top stocks recommended by analysts >>
SABS market cap is currently $39.31M and has a P/E ratio of -1.35.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blue Calypso Inc is engaged in the development, sales, delivery and licensing of technology and intellectual property focused on mobile shopper engagement, digital word of mouth and location-based marketing and advertising. Its solutions include mobile engagement, POP and merchandise tracking, mobile plant tag engagement. The company derives its revenues from the cloud-based consumption of its technology platform, consulting fees and licensing of its technologies.
Read More on SABS:
- SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results
- SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
- SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform
- SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11
- SAB Biotherapeutics files to sell 300K shares of common stock for holders
